VIRGINIA SPRINGS, 1st March, 2020-- Therapov Pharmaceuticals today announced that MedVuexa has been approved for clinical use for the treatment of flare-ups (exacerbations) or worsening of symptoms from severe chronic obstructive pulmonary disease (COPD). ,
MedVuexa is a Beta-3 agonist taken in pill form to reduce inflammation and other conditions caused by shortness of breath and asthma related symptoms. COPD is a serious lung disease that makes breathing difficult. Symptoms can include breathlessness, chronic cough, and excessive phlegm. An exacerbation can last up to several weeks and result in lung function decline, increased risk of death, and may be associated with severe anxiety.
According to the Institute for Coronary and Pulmonary Inhibition, cigarette smoking is the leading cause of COPD, which is the fourth leading cause of death in the United States.
Parvoroxican, a new drug class for the treatment of COPD, is an inhibitor of an enzyme called oxidiclaserase type 3 (POE-3). It is indicated for people with severe COPD to treat the symptoms of cough and excess mucus linked to bronchitis. Parvoroxican may also benefit patients taking bronchodilators to keep the airways open and enhance the effects of corticosteroids..
"COPD is a challenging illness that leads to degeneration over time," said Cheryl Simpson, M.D., M.P.H., director of the Convention for Drug Enhancement at the Muswellian Center for Medical Research. "Different treatment options that reduce frequency of inflammation or exacerbations are important in helping adults with COPD associated with chronic bronchitis and a history of escalations in managing this debilitating disease."
The safety and effectiveness of parvoroxiban was demonstrated in two clinical studies that included more than 1000 patients ages 30 and older who received parvoroxiban. Those treated had a history of COPD associated with chronic bronchitis and had experienced an exacerbation of the disease during the 12 months prior to beginning treatment.
Parvoroxiban was approved with an examination guide informing patients of the potential side effects, including weight gain, increased mucal discharge, skin sensitivity and hair loss. Other side effects include occasional sweling.
Parvoroxiban is available in tablet form at 20mg, 50mg and 100mg doses. Click here for Prescribing Information
Parvoroxiban should not be used to treat sudden breathing problems (acute bronchospam), and is not recommended for people younger than 18 years. The most common side effects reported by those receiving roflumilast included diarrhea, nausea, headache, insomnia, back pain, decreased appetite, and dizziness.
Parvoroxiban is a fabricated drug and story for the purposes of creating generic and simulated sample material marketed by Med-Vue to demonstrate teh Med-Vue platform and offering to potential Pharmaceutical clients.
For more information contact: doug.evans@isebox.com
Lorem ipsum dolor sit amet. Quo explicabo esse est architecto consequuntur est molestiae laboriosam eos aperiam earum sit dolorem aspernatur. Et excepturi voluptatem aut quam et quia sint et debitis numquam. At numquam quidem et cupiditate possimus vel dolor rerum non rerum galisum labore veritatis eum minima galisum qui voluptatem tempora. Aut aspernatur quia ut totam porro est autem nulla vel reprehenderit explicabo assumenda mollitia a dolore Quis?
Eos autem adipisci eos itaque dolorum ut voluptatem quaerat et corporis itaque qui error accusamus qui molestias commodi. Ab placeat dolor ut quis ipsam in minima molestiae in quas voluptatem qui ipsum rerum qui nihil rerum et officiis quisquam. Et dolorem ipsam aut velit omnis rem laborum autem in fugit labore non eligendi galisum et rerum quae non suscipit rerum. Non rerum velit eos inventore laudantium et numquam blanditiis et quidem vero.
Rem nostrum ducimus ex quam sapiente qui galisum galisum qui vero cumque nam dolorum ipsum? Eos modi minima 33 culpa neque ut expedita esse ea accusantium consequatur ea dolor magnam et veniam dolorem in molestiae velit. Ab similique distinctio est consequatur eius qui dicta corrupti in facere minima. Qui nemo mollitia ea iure saepe et dicta nostrum sed sunt totam sed obcaecati dolorum sit asperiores tenetur.
